Pentapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-16. Numbers and descriptions here follow the published literature rather than marketing material.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
| Property | Value | Notes |
|---|---|---|
| Purity method | Reversed-phase HPLC | C18 column, UV detection at 214 nm |
| Identity method | Mass spectrometry | Electrospray or MALDI-TOF |
| Solubility | Soluble in water and DMSO | Dissolution may require brief mixing |
| Storage temperature | -20 °C or lower | Desiccated and protected from light |
| Counterion form | Trifluoroacetate or acetate | Affects measured peptide content |
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
The soap is then cut into cubes. The cubes of soap are stacked in staggered cylinders to allow maximum air exposure. Once they have dried sufficiently, they are put into a special subterranean chamber to be aged for six months to a year. While it is aging, the soap goes through several chemical changes. The free alkaline content of the soap (the alkaline which did not react with the oil during saponification) breaks down upon slow reaction with air. The moisture content of the soap is also reduced, making the soap hard and long-lasting. And lastly, the color of the outside of the soap turns pale gold, while the inside remains green. Modern Aleppo soaps are manufactured using a "cold process" and contain olive and laurel oils, and may contain a variety of herbs and/or essential oils.
N2 is mostly used as a filler gas to prevent pack collapse. In addition, it is also used to prevent oxidative rancidity in packaged products such as snack foods by displacing atmospheric air, especially oxygen, therefore extending shelf life. The use of noble gases such as helium (He), argon (Ar) and xenon (Xe) to replace N2 as the balancing gas in MAP can also be used to preserve and extend the shelf life of fresh and minimally processed fruits and vegetables. Their beneficial effects are due to their higher solubility and diffusivity in water, making them more effective in displacing O2 from cellular sites and enzymatic O2 receptors. There has been a debate regarding the use of carbon monoxide (CO) in the packaging of red meat due to its possible toxic effect on packaging workers. Its use results in a more stable red color of carboxymyoglobin in meat, which leads to another concern that it can mask evidence of spoilage in the product.
=== Taste === The perceived garlic taste upon skin contact with DMSO may be due to nonolfactory activation of TRPA1 receptors in trigeminal ganglia. Unlike dimethyl and diallyl disulfides (which have odors resembling garlic), mono- and tri- sulfides (which typically have foul odors), and similar odiferous sulfur compounds, the pure chemical DMSO is odorless.
Sources: en.wikipedia.org
In the 1950s the neurotransmitter dopamine was discovered in the brain by Katharine Montagu, and characterised as a neurotransmitter a year later by Arvid Carlsson, for which he would be awarded the Nobel Prize. A. N. Ernst then discovered in 1965 that apomorphine was a powerful stimulant of dopamine receptors. This, along with the use of sublingual apomorphine tablets, led to a renewed interest in the use of apomorphine as a treatment for alcoholism. A series of studies of non-emetic apomorphine in the treatment of alcoholism were published, with mostly positive results. However, there was little clinical consequence.
Activation of the PI3K–AKT signaling pathway by insulin-like growth factor 1 (IGF1) or by AKT2 overexpression led to the upregulation of CUX1 and was associated with resistance to apoptosis, whereas treatment of cells with the PI3K inhibitor LY294002 decreased CUX1 expression and increased apoptosis. Whether the discrepancies in the results and conclusions from these two studies can be explained by differences in cell-types or other reasons remains to be verified. The auxiliary role of CUX1 in base excision repair has raised the possibility that its tumor suppressor function may be linked to its function in DNA repair. CUX1 knockdown delays DNA repair in multiple cell lines. Mouse embryo fibroblasts (MEFs) derived from a Cux1-/- knockout mouse exhibit increased genomic instability23, moreover Cux1+/−- heterozygous MEFs are haploinsufficient for DNA repair18. Yet, whether CUX1 hemizygosity augments the risk of cancer by increasing the frequency of mutations and/or genomic rearrangements remains to be formally tested.
dipole moment See electric dipole moment, magnetic dipole moment, molecular dipole moment, bond dipole moment, electron electric dipole moment, electron magnetic dipole moment, and nuclear magnetic moment.
25 June – Astronomers report the discovery and confirmation of two unusually low-density exoplanets, TOI-791 b and TOI-791 c, orbiting the star TOI-791 about 1,113 light-years from Earth. Detected using NASA's Transiting Exoplanet Survey Satellite, the Jupiter-sized "super-puff" planets have densities of 0.038 and 0.047 g/cm3, respectively, making them among the lowest-density giant planets known and the largest planets yet found with densities below 0.05 g/cm3. 29 June – Palaeontologists identify a fossil vertebra collected on James Ross Island in 1985 as the earliest-known dinosaur bone collected in Antarctica. The specimen, stored for 40 years in the British Antarctic Survey collections, is confirmed to be a tail bone from a titanosaur, a group of long-necked sauropod dinosaurs. The animal is estimated to have lived about 82 million years ago, during the Late Cretaceous, when Antarctica was covered in forest. 30 June – Astronomers report a revised orbit and mass for the nearby habitable zone super-Earth GJ 3378 b. Combining radial velocity data from the Habitable-zone Planet Finder, NEID, CARMENES and SPIRou spectrometers, the team finds that the planet has an orbital period of 21.45 days and a minimum mass of 2.3 Earth masses, rather than earlier estimates of 24.73 days and 5.26 Earth masses. The revision leaves the planet within the conservative liquid-water habitable zone of its red dwarf host star, increases the likelihood that it has a terrestrial composition, and suggests that it may have retained an atmosphere despite high X-ray and ultraviolet exposure.
Sources: en.wikipedia.org
=== Mixed with polyketides === Due to the similarity with polyketide synthases (PKS), many secondary metabolites are, in fact, fusions of NRPs and polyketides. In essence, this occurs when PK modules follow NRP modules, and vice versa. This is possible because the carrier domains (PCP/ACP) are quite similar between each other and they use a similar "chain-flipping" action to access the growing substrate. Although there is high degree of similarity between the Carrier (PCP/ACP) domains of both types of synthetases, the mechanism of condensation is different from a chemical standpoint:
However, there has been criticism where it favors the idea for lips, with the 2017 analytical study proposing that tyrannosaurids had large, flat scales on their snouts instead of lips, as modern crocodiles do. But crocodiles possess rather cracked keratinized skin, not flat scales; by observing the hummocky rugosity of tyrannosaurids, and comparing it to extant lizards, researchers have found that tyrannosaurids had squamose scales rather than a crocodillian-like skin. In 2023, Cullen and colleagues supported the idea that theropods like tyrannosaurids had lips based on anatomical patterns, such as those of the foramina on their face and jaws, more similar to those of modern squamates such as monitor lizards or marine iguanas than those of modern crocodilians like alligators. Comparison of the teeth of Daspletosaurus and American alligators shows that the enamel of tyrannosaurids had no significant wear and that the teeth of modern crocodilians were eroded on the labial side and were substantially worn. This suggests that it is likely that theropod teeth were kept wet by lips. On the basis of the relationship between hydration and wear resistance, the authors argued that it is unlikely that the teeth of theropods, including tyrannosaurids, would have remained unworn when exposed for a long time, because it would have been hard to maintain hydration.
In molecular biology, fibrous proteins or scleroproteins are one of the three main classifications of protein structure (alongside globular and membrane proteins). Fibrous proteins are made up of elongated or fibrous polypeptide chains which form filamentous and sheet-like structures. This kind of protein can be distinguished from globular protein by its low solubility in water. In contrast, globular proteins are spherical and generally soluble in water, performing dynamic functions like enzymatic activity or transport. Such proteins serve protective and structural roles by forming connective tissue, tendons, bone matrices, and muscle fiber. Fibrous proteins consist of many families including keratin, collagen, elastin, fibrin or spidroin. Collagen is the most abundant of these proteins which exists in vertebrate connective tissue including tendon, cartilage, and bone.
=== Chemistry === Like the other noble gases, krypton is chemically highly unreactive. The rather restricted chemistry of krypton in the +2 oxidation state parallels that of the neighboring element bromine in the +1 oxidation state; due to the scandide contraction it is difficult to oxidize the 4p elements to their group oxidation states. Until the 1960s no noble gas compounds had been synthesized. Following the first successful synthesis of xenon compounds in 1962, synthesis of krypton difluoride (KrF2) was reported in 1963. In the same year, KrF4 was reported by Grosse, et al., but was subsequently shown to be a mistaken identification. Under extreme conditions, krypton reacts with fluorine to form KrF2 according to the following equation:
=== Planning and decision-making === An "agent" is any entity (artificial or not) that perceives and takes actions in the world. A rational agent has goals or preferences and takes actions to make them happen. In automated planning, the agent has a specific goal. In automated decision-making, the agent has preferences—there are some situations it would prefer to be in, and some situations it is trying to avoid. The decision-making agent assigns a number to each situation (called its "utility") that measures how much the agent prefers it. For each possible action, it can calculate the "expected utility": the utility of all possible outcomes of the action, weighted by the probability that the outcome will occur. It can then choose the action with the maximum expected utility. In classical planning, the agent knows exactly what the effect of any action will be. In most real-world problems, however, the agent may not understand its current situation with certainty (it is "unknown" or "unobservable") and it may not know for certain what will happen after each possible action (it is not "deterministic"). It must choose an action by making a probabilistic guess and then reassess the situation to see if the action had the desired effect. Alongside thorough testing and improvement based on previous decisions, having an explanation for why the agent took certain decisions is a way to build trust, especially when the decisions have to be relied upon. In some problems, the agent's preferences may be uncertain, especially if there are other agents or humans involved.
Sources: en.wikipedia.org
It is reported as the percentage of total peak area in a reversed-phase chromatogram. That number does not reflect water content, residual solvents, or counterions. The actual peptide content is therefore lower than the stated purity figure suggests.
Trifluoroacetate and acetate are common in lyophilized peptide preparations. They contribute to the mass of the powder without contributing to the peptide itself. This shifts the true content and can affect results in biological assays.
Hydrolysis and oxidation are the primary pathways. Alkaline conditions accelerate hydrolytic cleavage of the chain. Oxidation most often involves susceptible residues, producing products that appear as earlier or later peaks in chromatographic analysis.
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.